J Korean Med Sci.  2017 Oct;32(10):1708-1712. 10.3346/jkms.2017.32.10.1708.

Intramyocardial Injection of Stem Cells in Pig Myocardial Infarction Model: The First Trial in Korea

• Kim MC
• Kim YS
• Kang WS
• Lee KH
• Cho M
• Hong MH
• Lim KS
• Jeong MH
• Ahn Y

• KMID: 2400446
• DOI: http://doi.org/10.3346/jkms.2017.32.10.1708

Abstract

Although cell therapy is emerged for cardiac repair, its efficacy is modest by intracoronary infusion. Therefore, we established the intramyocardial delivery technique using a left ventricular (LV) mapping system (NOGA® XP) using 18 pigs. After adipose tissue-derived mesenchymal stem cells (ATSCs) were delivered intramyocardially to porcine infarcted heart, LV ejection fraction (EF) was increased, and LV chamber size was decreased. We proved the therapeutic effect of intramyocardial injection of ATSC through a LV mapping system in the porcine model for the first time in Korea. The adoption of this technique may accelerate the translation into a clinical application in the near future.

Keyword

Mesenchymal Stem Cell Transplantation; Heart Failure; Myocardial Infarction

MeSH Terms

Cell- and Tissue-Based Therapy
Heart
Heart Failure
Korea*
Mesenchymal Stem Cell Transplantation
Mesenchymal Stromal Cells
Myocardial Infarction*
Stem Cells*
Swine

Figure

• 

  Fig. 1 Comparisons of infarct size by visual estimation between 1 week and 4 weeks post-AMI in cell injected pig (purple dots). (A, B) Anteroposterior (1 week and 4 weeks) and (C, D) right anterior oblique (1 week and 4 weeks) projections. Infarct size was reduced on bipolar voltage map 4 weeks after AMI. AMI = acute myocardial infarction.

• 

  Fig. 2 Comparisons of infarct size by visual estimation between 1 week and 4 weeks post-AMI in control pig. (A, B) Anteroposterior (1 week and 4 weeks) and (C, D) right anterior oblique (1 week and 4 weeks) projections. There was an extension of infarct size in control pig. AMI = acute myocardial infarction.

Reference

1. Choi DJ, Han S, Jeon ES, Cho MC, Kim JJ, Yoo BS, Shin MS, Seong IW, Ahn Y, Kang SM, et al. Registry. Characteristics, outcomes and predictors of long-term mortality for patients hospitalized for acute heart failure: a report from the Korean heart failure registry. Korean Circ J. 2011; 41:363–371.

2. McMurray JJ. Clinical practice. Systolic heart failure. N Engl J Med. 2010; 362:228–238.

3. Ibáñez B, Heusch G, Ovize M, Van de Werf F. Evolving therapies for myocardial ischemia/reperfusion injury. J Am Coll Cardiol. 2015; 65:1454–1471.

4. Gyöngyösi M, Wojakowski W, Lemarchand P, Lunde K, Tendera M, Bartunek J, Marban E, Assmus B, Henry TD, Traverse JH, et al. ACCRUE Investigators. Meta-Analysis of Cell-based CaRdiac stUdiEs (ACCRUE) in patients with acute myocardial infarction based on individual patient data. Circ Res. 2015; 116:1346–1360.

5. Charwat S, Lang I, Dettke M, Graf S, Nyolczas N, Hemetsberger R, Zamini S, Khorsand A, Sochor H, Maurer G, et al. Effect of intramyocardial delivery of autologous bone marrow mononuclear stem cells on the regional myocardial perfusion. NOGA-guided subanalysis of the MYSTAR prospective randomised study. Thromb Haemost. 2010; 103:564–571.

6. Williams AR, Hare JM. Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ Res. 2011; 109:923–940.

7. Kim YS, Kwon JS, Hong MH, Kang WS, Jeong HY, Kang HJ, Jeong M, Ahn Y. Restoration of angiogenic capacity of diabetes-insulted mesenchymal stem cells by oxytocin. BMC Cell Biol. 2013; 14:38.

8. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005; 18:1440–1463.

9. Clifford DM, Fisher SA, Brunskill SJ, Doree C, Mathur A, Clarke MJ, Watt SM, Martin-Rendon E. Long-term effects of autologous bone marrow stem cell treatment in acute myocardial infarction: factors that may influence outcomes. PLoS One. 2012; 7:e37373.

10. Gyöngyösi M, Dib N. Diagnostic and prognostic value of 3D NOGA mapping in ischemic heart disease. Nat Rev Cardiol. 2011; 8:393–404.

11. Gyöngyösi M, Lang I, Dettke M, Beran G, Graf S, Sochor H, Nyolczas N, Charwat S, Hemetsberger R, Christ G, et al. Combined delivery approach of bone marrow mononuclear stem cells early and late after myocardial infarction: the MYSTAR prospective, randomized study. Nat Clin Pract Cardiovasc Med. 2009; 6:70–81.

12. Heldman AW, DiFede DL, Fishman JE, Zambrano JP, Trachtenberg BH, Karantalis V, Mushtaq M, Williams AR, Suncion VY, McNiece IK, et al. Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial. JAMA. 2014; 311:62–73.

13. Trachtenberg B, Velazquez DL, Williams AR, McNiece I, Fishman J, Nguyen K, Rouy D, Altman P, Schwarz R, Mendizabal A, et al. Rationale and design of the Transendocardial Injection of Autologous Human Cells (bone marrow or mesenchymal) in Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction (TAC-HFT) trial: a randomized, double-blind, placebo-controlled study of safety and efficacy. Am Heart J. 2011; 161:487–493.

14. Williams AR, Trachtenberg B, Velazquez DL, McNiece I, Altman P, Rouy D, Mendizabal AM, Pattany PM, Lopera GA, Fishman J, et al. Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: functional recovery and reverse remodeling. Circ Res. 2011; 108:792–796.

15. Pokushalov E, Romanov A, Chernyavsky A, Larionov P, Terekhov I, Artyomenko S, Poveshenko O, Kliver E, Shirokova N, Karaskov A, et al. Efficiency of intramyocardial injections of autologous bone marrow mononuclear cells in patients with ischemic heart failure: a randomized study. J Cardiovasc Transl Res. 2010; 3:160–168.

16. Bartunek J, Behfar A, Dolatabadi D, Vanderheyden M, Ostojic M, Dens J, El Nakadi B, Banovic M, Beleslin B, Vrolix M, et al. Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. J Am Coll Cardiol. 2013; 61:2329–2338.